Ontology type: schema:ScholarlyArticle
2021-12-01
AUTHORSIlias Vachliotis, Antonis Goulas, Paraskevi Papaioannidou, Stergios A. Polyzos
ABSTRACTNonalcoholic fatty liver disease (NAFLD) is a metabolic disorder whose current rapidly expanding prevalence is causing it to develop into a major global health concern. NAFLD is closely linked to the modern, unhealthy lifestyle. The Western diet, characterized by excessive energy intake, frequent consumption of red meat, processed meat and foods, soft drinks, and sugar-sweetened beverages (SSBs), irregular meal distribution throughout the day, and unhealthy ways of cooking, predisposes to development of NAFLD. Low levels of physical activity and prolonged sedentary time are additional lifestyle risk factors for NAFLD. Given the present lack of effective pharmacological treatment, lifestyle modifications are regarded as the cornerstone of NAFLD management. Reducing daily calorie intake together with following the Mediterranean diet (MD) is an increasingly accepted approach. Furthermore, increasing the level of physical activity and limiting sedentary behavior are additional measures proposed to improve the outcomes of the disease. Apart from being affected by lifestyle, NAFLD may also affect patients’ quality of life (QoL), mostly in the domain of physical function. In this regard, while the early and more benign form of the disease, i.e., simple hepatic steatosis, may not affect QoL, there is evidence, though conflicting, of the impact of nonalcoholic steatohepatitis (NASH) on this index, with, however, most studies showing that QoL is consistently affected in advanced disease, i.e., hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Considering all the above, appropriate management of lifestyle is likely to attenuate the severity of the disease and improve the QoL of NAFLD patients. More... »
PAGES41-49
http://scigraph.springernature.com/pub.10.1007/s42000-021-00339-6
DOIhttp://dx.doi.org/10.1007/s42000-021-00339-6
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1143530072
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34854066
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Energy Intake",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Life Style",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Liver",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Liver Cirrhosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Non-alcoholic Fatty Liver Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Quality of Life",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece",
"id": "http://www.grid.ac/institutes/grid.4793.9",
"name": [
"80th Battalion of Medical Corps, General Ioannis Makrygiannis Camp, Pyli, Kos, Greece",
"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"
],
"type": "Organization"
},
"familyName": "Vachliotis",
"givenName": "Ilias",
"type": "Person"
},
{
"affiliation": {
"alternateName": "First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece",
"id": "http://www.grid.ac/institutes/grid.4793.9",
"name": [
"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"
],
"type": "Organization"
},
"familyName": "Goulas",
"givenName": "Antonis",
"id": "sg:person.014754376524.89",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014754376524.89"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece",
"id": "http://www.grid.ac/institutes/grid.4793.9",
"name": [
"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"
],
"type": "Organization"
},
"familyName": "Papaioannidou",
"givenName": "Paraskevi",
"id": "sg:person.015615620427.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015615620427.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece",
"id": "http://www.grid.ac/institutes/grid.4793.9",
"name": [
"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"
],
"type": "Organization"
},
"familyName": "Polyzos",
"givenName": "Stergios A.",
"id": "sg:person.0720405206.87",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720405206.87"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00394-018-1711-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1103973733",
"https://doi.org/10.1007/s00394-018-1711-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ejcn.2012.220",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025016687",
"https://doi.org/10.1038/ejcn.2012.220"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40200-019-00475-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1124936667",
"https://doi.org/10.1007/s40200-019-00475-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12876-020-01204-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1125615597",
"https://doi.org/10.1186/s12876-020-01204-3"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-12-01",
"datePublishedReg": "2021-12-01",
"description": "Abstract\nNonalcoholic fatty liver disease (NAFLD) is a metabolic disorder whose current rapidly expanding prevalence is causing it to develop into a major global health concern. NAFLD is closely linked to the modern, unhealthy lifestyle. The Western diet, characterized by excessive energy intake, frequent consumption of red meat, processed meat and foods, soft drinks, and sugar-sweetened beverages (SSBs), irregular meal distribution throughout the day, and unhealthy ways of cooking, predisposes to development of NAFLD. Low levels of physical activity and prolonged sedentary time are additional lifestyle risk factors for NAFLD. Given the present lack of effective pharmacological treatment, lifestyle modifications are regarded as the cornerstone of NAFLD management. Reducing daily calorie intake together with following the Mediterranean diet (MD) is an increasingly accepted approach. Furthermore, increasing the level of physical activity and limiting sedentary behavior are additional measures proposed to improve the outcomes of the disease. Apart from being affected by lifestyle, NAFLD may also affect patients\u2019 quality of life (QoL), mostly in the domain of physical function. In this regard, while the early and more benign form of the disease, i.e., simple hepatic steatosis, may not affect QoL, there is evidence, though conflicting, of the impact of nonalcoholic steatohepatitis (NASH) on this index, with, however, most studies showing that QoL is consistently affected in advanced disease, i.e., hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Considering all the above, appropriate management of lifestyle is likely to attenuate the severity of the disease and improve the QoL of NAFLD patients.",
"genre": "article",
"id": "sg:pub.10.1007/s42000-021-00339-6",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1030758",
"issn": [
"1109-3099",
"2520-8721"
],
"name": "Hormones",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "21"
}
],
"keywords": [
"nonalcoholic fatty liver disease",
"sugar-sweetened beverages",
"quality of life",
"nonalcoholic steatohepatitis",
"physical activity",
"Mediterranean diet",
"development of NAFLD",
"major global health concern",
"simple hepatic steatosis",
"lifestyle risk factors",
"fatty liver disease",
"effective pharmacological treatment",
"excessive energy intake",
"global health concern",
"lifestyle modification",
"advanced disease",
"NAFLD patients",
"NAFLD management",
"liver disease",
"pharmacological treatment",
"physical function",
"hepatic steatosis",
"hepatic fibrosis",
"risk factors",
"Western diet",
"sedentary time",
"unhealthy lifestyle",
"hepatocellular carcinoma",
"sedentary behavior",
"metabolic disorders",
"daily calories",
"frequent consumption",
"meal distribution",
"appropriate management",
"energy intake",
"health concern",
"benign form",
"disease",
"red meat",
"QoL",
"patients",
"soft drinks",
"lifestyle",
"diet",
"most studies",
"low levels",
"additional measures",
"unhealthy ways",
"cirrhosis",
"steatohepatitis",
"steatosis",
"carcinoma",
"fibrosis",
"prevalence",
"intake",
"severity",
"disorders",
"calories",
"outcomes",
"management",
"levels",
"treatment",
"activity",
"life",
"drinks",
"meat",
"days",
"beverages",
"cornerstone",
"evidence",
"food",
"index",
"factors",
"present lack",
"quality",
"study",
"measures",
"lack",
"regard",
"concern",
"function",
"development",
"consumption",
"time",
"impact",
"cooking",
"modification",
"form",
"approach",
"domain",
"distribution",
"behavior",
"way"
],
"name": "Nonalcoholic fatty liver disease: lifestyle and quality of life",
"pagination": "41-49",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1143530072"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s42000-021-00339-6"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34854066"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s42000-021-00339-6",
"https://app.dimensions.ai/details/publication/pub.1143530072"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:38",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_876.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s42000-021-00339-6"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s42000-021-00339-6'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s42000-021-00339-6'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s42000-021-00339-6'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s42000-021-00339-6'
This table displays all metadata directly associated to this object as RDF triples.
220 TRIPLES
22 PREDICATES
130 URIs
118 LITERALS
14 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s42000-021-00339-6 | schema:about | N0e1d4dbe63ce4c8991df5d743ad47253 |
2 | ″ | ″ | N1856b2210d5a47f5b9908b2609931ada |
3 | ″ | ″ | N3d112398b287413f9fcd7139871cd1c7 |
4 | ″ | ″ | N4e14f35d345b4b19ac50ad7a819e51cf |
5 | ″ | ″ | N9e29d2c367ee4f57a81873daca9c55b3 |
6 | ″ | ″ | Nb703ff8f8508448aa9c645c278451707 |
7 | ″ | ″ | Nda97e32da0dc440696aa36006df8f5fe |
8 | ″ | ″ | anzsrc-for:11 |
9 | ″ | ″ | anzsrc-for:1103 |
10 | ″ | schema:author | Nd7385133389943c88596e69dcf7a3f59 |
11 | ″ | schema:citation | sg:pub.10.1007/s00394-018-1711-4 |
12 | ″ | ″ | sg:pub.10.1007/s40200-019-00475-2 |
13 | ″ | ″ | sg:pub.10.1038/ejcn.2012.220 |
14 | ″ | ″ | sg:pub.10.1186/s12876-020-01204-3 |
15 | ″ | schema:datePublished | 2021-12-01 |
16 | ″ | schema:datePublishedReg | 2021-12-01 |
17 | ″ | schema:description | Abstract Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder whose current rapidly expanding prevalence is causing it to develop into a major global health concern. NAFLD is closely linked to the modern, unhealthy lifestyle. The Western diet, characterized by excessive energy intake, frequent consumption of red meat, processed meat and foods, soft drinks, and sugar-sweetened beverages (SSBs), irregular meal distribution throughout the day, and unhealthy ways of cooking, predisposes to development of NAFLD. Low levels of physical activity and prolonged sedentary time are additional lifestyle risk factors for NAFLD. Given the present lack of effective pharmacological treatment, lifestyle modifications are regarded as the cornerstone of NAFLD management. Reducing daily calorie intake together with following the Mediterranean diet (MD) is an increasingly accepted approach. Furthermore, increasing the level of physical activity and limiting sedentary behavior are additional measures proposed to improve the outcomes of the disease. Apart from being affected by lifestyle, NAFLD may also affect patients’ quality of life (QoL), mostly in the domain of physical function. In this regard, while the early and more benign form of the disease, i.e., simple hepatic steatosis, may not affect QoL, there is evidence, though conflicting, of the impact of nonalcoholic steatohepatitis (NASH) on this index, with, however, most studies showing that QoL is consistently affected in advanced disease, i.e., hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Considering all the above, appropriate management of lifestyle is likely to attenuate the severity of the disease and improve the QoL of NAFLD patients. |
18 | ″ | schema:genre | article |
19 | ″ | schema:inLanguage | en |
20 | ″ | schema:isAccessibleForFree | false |
21 | ″ | schema:isPartOf | N17384904b3b5464e984748bbea2cae49 |
22 | ″ | ″ | Naa00bbdf879b47cda91eb0668190bf5d |
23 | ″ | ″ | sg:journal.1030758 |
24 | ″ | schema:keywords | Mediterranean diet |
25 | ″ | ″ | NAFLD management |
26 | ″ | ″ | NAFLD patients |
27 | ″ | ″ | QoL |
28 | ″ | ″ | Western diet |
29 | ″ | ″ | activity |
30 | ″ | ″ | additional measures |
31 | ″ | ″ | advanced disease |
32 | ″ | ″ | approach |
33 | ″ | ″ | appropriate management |
34 | ″ | ″ | behavior |
35 | ″ | ″ | benign form |
36 | ″ | ″ | beverages |
37 | ″ | ″ | calories |
38 | ″ | ″ | carcinoma |
39 | ″ | ″ | cirrhosis |
40 | ″ | ″ | concern |
41 | ″ | ″ | consumption |
42 | ″ | ″ | cooking |
43 | ″ | ″ | cornerstone |
44 | ″ | ″ | daily calories |
45 | ″ | ″ | days |
46 | ″ | ″ | development |
47 | ″ | ″ | development of NAFLD |
48 | ″ | ″ | diet |
49 | ″ | ″ | disease |
50 | ″ | ″ | disorders |
51 | ″ | ″ | distribution |
52 | ″ | ″ | domain |
53 | ″ | ″ | drinks |
54 | ″ | ″ | effective pharmacological treatment |
55 | ″ | ″ | energy intake |
56 | ″ | ″ | evidence |
57 | ″ | ″ | excessive energy intake |
58 | ″ | ″ | factors |
59 | ″ | ″ | fatty liver disease |
60 | ″ | ″ | fibrosis |
61 | ″ | ″ | food |
62 | ″ | ″ | form |
63 | ″ | ″ | frequent consumption |
64 | ″ | ″ | function |
65 | ″ | ″ | global health concern |
66 | ″ | ″ | health concern |
67 | ″ | ″ | hepatic fibrosis |
68 | ″ | ″ | hepatic steatosis |
69 | ″ | ″ | hepatocellular carcinoma |
70 | ″ | ″ | impact |
71 | ″ | ″ | index |
72 | ″ | ″ | intake |
73 | ″ | ″ | lack |
74 | ″ | ″ | levels |
75 | ″ | ″ | life |
76 | ″ | ″ | lifestyle |
77 | ″ | ″ | lifestyle modification |
78 | ″ | ″ | lifestyle risk factors |
79 | ″ | ″ | liver disease |
80 | ″ | ″ | low levels |
81 | ″ | ″ | major global health concern |
82 | ″ | ″ | management |
83 | ″ | ″ | meal distribution |
84 | ″ | ″ | measures |
85 | ″ | ″ | meat |
86 | ″ | ″ | metabolic disorders |
87 | ″ | ″ | modification |
88 | ″ | ″ | most studies |
89 | ″ | ″ | nonalcoholic fatty liver disease |
90 | ″ | ″ | nonalcoholic steatohepatitis |
91 | ″ | ″ | outcomes |
92 | ″ | ″ | patients |
93 | ″ | ″ | pharmacological treatment |
94 | ″ | ″ | physical activity |
95 | ″ | ″ | physical function |
96 | ″ | ″ | present lack |
97 | ″ | ″ | prevalence |
98 | ″ | ″ | quality |
99 | ″ | ″ | quality of life |
100 | ″ | ″ | red meat |
101 | ″ | ″ | regard |
102 | ″ | ″ | risk factors |
103 | ″ | ″ | sedentary behavior |
104 | ″ | ″ | sedentary time |
105 | ″ | ″ | severity |
106 | ″ | ″ | simple hepatic steatosis |
107 | ″ | ″ | soft drinks |
108 | ″ | ″ | steatohepatitis |
109 | ″ | ″ | steatosis |
110 | ″ | ″ | study |
111 | ″ | ″ | sugar-sweetened beverages |
112 | ″ | ″ | time |
113 | ″ | ″ | treatment |
114 | ″ | ″ | unhealthy lifestyle |
115 | ″ | ″ | unhealthy ways |
116 | ″ | ″ | way |
117 | ″ | schema:name | Nonalcoholic fatty liver disease: lifestyle and quality of life |
118 | ″ | schema:pagination | 41-49 |
119 | ″ | schema:productId | N17a3ccac6f4149a382918cb64bb6263b |
120 | ″ | ″ | N830be12374c2412cbc38cb21b619849f |
121 | ″ | ″ | N8e955669582c46d38afae0e780283683 |
122 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1143530072 |
123 | ″ | ″ | https://doi.org/10.1007/s42000-021-00339-6 |
124 | ″ | schema:sdDatePublished | 2022-05-20T07:38 |
125 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
126 | ″ | schema:sdPublisher | N9e5a1ae035d94ad9832a5056dcb5d74d |
127 | ″ | schema:url | https://doi.org/10.1007/s42000-021-00339-6 |
128 | ″ | sgo:license | sg:explorer/license/ |
129 | ″ | sgo:sdDataset | articles |
130 | ″ | rdf:type | schema:ScholarlyArticle |
131 | N0e1d4dbe63ce4c8991df5d743ad47253 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
132 | ″ | schema:name | Liver Cirrhosis |
133 | ″ | rdf:type | schema:DefinedTerm |
134 | N17384904b3b5464e984748bbea2cae49 | schema:issueNumber | 1 |
135 | ″ | rdf:type | schema:PublicationIssue |
136 | N17a3ccac6f4149a382918cb64bb6263b | schema:name | dimensions_id |
137 | ″ | schema:value | pub.1143530072 |
138 | ″ | rdf:type | schema:PropertyValue |
139 | N1856b2210d5a47f5b9908b2609931ada | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
140 | ″ | schema:name | Non-alcoholic Fatty Liver Disease |
141 | ″ | rdf:type | schema:DefinedTerm |
142 | N206d652d0106462b9113b8534c7fbe78 | schema:affiliation | grid-institutes:grid.4793.9 |
143 | ″ | schema:familyName | Vachliotis |
144 | ″ | schema:givenName | Ilias |
145 | ″ | rdf:type | schema:Person |
146 | N2f0f60a9374f4555b52c7cf61364a660 | rdf:first | sg:person.014754376524.89 |
147 | ″ | rdf:rest | N6cc88830398a4f7f9454af5f14f98951 |
148 | N31da088e6d524305be90304fdf7c9fc5 | rdf:first | sg:person.0720405206.87 |
149 | ″ | rdf:rest | rdf:nil |
150 | N3d112398b287413f9fcd7139871cd1c7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
151 | ″ | schema:name | Quality of Life |
152 | ″ | rdf:type | schema:DefinedTerm |
153 | N4e14f35d345b4b19ac50ad7a819e51cf | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
154 | ″ | schema:name | Liver |
155 | ″ | rdf:type | schema:DefinedTerm |
156 | N6cc88830398a4f7f9454af5f14f98951 | rdf:first | sg:person.015615620427.20 |
157 | ″ | rdf:rest | N31da088e6d524305be90304fdf7c9fc5 |
158 | N830be12374c2412cbc38cb21b619849f | schema:name | pubmed_id |
159 | ″ | schema:value | 34854066 |
160 | ″ | rdf:type | schema:PropertyValue |
161 | N8e955669582c46d38afae0e780283683 | schema:name | doi |
162 | ″ | schema:value | 10.1007/s42000-021-00339-6 |
163 | ″ | rdf:type | schema:PropertyValue |
164 | N9e29d2c367ee4f57a81873daca9c55b3 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
165 | ″ | schema:name | Energy Intake |
166 | ″ | rdf:type | schema:DefinedTerm |
167 | N9e5a1ae035d94ad9832a5056dcb5d74d | schema:name | Springer Nature - SN SciGraph project |
168 | ″ | rdf:type | schema:Organization |
169 | Naa00bbdf879b47cda91eb0668190bf5d | schema:volumeNumber | 21 |
170 | ″ | rdf:type | schema:PublicationVolume |
171 | Nb703ff8f8508448aa9c645c278451707 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
172 | ″ | schema:name | Humans |
173 | ″ | rdf:type | schema:DefinedTerm |
174 | Nd7385133389943c88596e69dcf7a3f59 | rdf:first | N206d652d0106462b9113b8534c7fbe78 |
175 | ″ | rdf:rest | N2f0f60a9374f4555b52c7cf61364a660 |
176 | Nda97e32da0dc440696aa36006df8f5fe | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
177 | ″ | schema:name | Life Style |
178 | ″ | rdf:type | schema:DefinedTerm |
179 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
180 | ″ | schema:name | Medical and Health Sciences |
181 | ″ | rdf:type | schema:DefinedTerm |
182 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
183 | ″ | schema:name | Clinical Sciences |
184 | ″ | rdf:type | schema:DefinedTerm |
185 | sg:journal.1030758 | schema:issn | 1109-3099 |
186 | ″ | ″ | 2520-8721 |
187 | ″ | schema:name | Hormones |
188 | ″ | schema:publisher | Springer Nature |
189 | ″ | rdf:type | schema:Periodical |
190 | sg:person.014754376524.89 | schema:affiliation | grid-institutes:grid.4793.9 |
191 | ″ | schema:familyName | Goulas |
192 | ″ | schema:givenName | Antonis |
193 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014754376524.89 |
194 | ″ | rdf:type | schema:Person |
195 | sg:person.015615620427.20 | schema:affiliation | grid-institutes:grid.4793.9 |
196 | ″ | schema:familyName | Papaioannidou |
197 | ″ | schema:givenName | Paraskevi |
198 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015615620427.20 |
199 | ″ | rdf:type | schema:Person |
200 | sg:person.0720405206.87 | schema:affiliation | grid-institutes:grid.4793.9 |
201 | ″ | schema:familyName | Polyzos |
202 | ″ | schema:givenName | Stergios A. |
203 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720405206.87 |
204 | ″ | rdf:type | schema:Person |
205 | sg:pub.10.1007/s00394-018-1711-4 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1103973733 |
206 | ″ | ″ | https://doi.org/10.1007/s00394-018-1711-4 |
207 | ″ | rdf:type | schema:CreativeWork |
208 | sg:pub.10.1007/s40200-019-00475-2 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1124936667 |
209 | ″ | ″ | https://doi.org/10.1007/s40200-019-00475-2 |
210 | ″ | rdf:type | schema:CreativeWork |
211 | sg:pub.10.1038/ejcn.2012.220 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1025016687 |
212 | ″ | ″ | https://doi.org/10.1038/ejcn.2012.220 |
213 | ″ | rdf:type | schema:CreativeWork |
214 | sg:pub.10.1186/s12876-020-01204-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1125615597 |
215 | ″ | ″ | https://doi.org/10.1186/s12876-020-01204-3 |
216 | ″ | rdf:type | schema:CreativeWork |
217 | grid-institutes:grid.4793.9 | schema:alternateName | First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece |
218 | ″ | schema:name | 80th Battalion of Medical Corps, General Ioannis Makrygiannis Camp, Pyli, Kos, Greece |
219 | ″ | ″ | First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece |
220 | ″ | rdf:type | schema:Organization |